OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (OTCBB: TBIO) today announced the appointment of John M. McAuliffe as Vice President of Business Development, Neurology, and Matthew W. Beer as Vice President of Business Development, Oncology. Mr. McAuliffe and Mr. Beer have strong backgrounds in business development for the life sciences and will lead the Company’s expansion efforts in their respective areas of focus. “John and Matt are key additions to the Transgenomic business development team, whose expansion represents our commitment to maximizing growth in the global commercial marketplace for genetic testing," stated Craig Tuttle, Chief Executive Officer of Transgenomic. "Their respective histories of leading successful companies through significant periods of expansion and growth will prove invaluable as we pursue new strategic partnering opportunities and broaden the reach of our innovative products and services, including our breakthrough blood-based cancer gene testing technology, ICE COLD-PCR."
